ArticleOncogene2026

TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation.

Xi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.